
Collagen Matrix today announced the acquisition of Polyganics, a medical technology company that develops and manufactures bioresorbable medical devices.
The acquisition expands Collagen Matrix's portfolio of bioresorbable solutions and technology platforms for bone and tissue repair, unlocking new markets and clinical opportunities for the Company.
As a provider of collagen-based medical products, Collagen Matrix has established a pipeline to meet the clinical needs of physicians across several verticals including dental, orthopedic, spine, dural repair, nerve repair, sports medicine and advanced wound care. With the addition of Polyganics' versatile polymer platform, Collagen Matrix will enter ear, nose and throat (ENT) and general surgery while expanding its offerings for neurosurgery and peripheral nerve — and will have the opportunity to deliver products that bring benefits of collagen plus polymers.
"This transaction broadens our breadth of capabilities significantly with new processes, technologies and products," added McCarthy. "We add value to our customers immediately by meeting a wider range of clinical needs. This transaction also fuels our innovation pipeline so we can continue bringing a number of new products to market each year." Continued Jeff Nelson, Chairman of the Board of Collagen Matrix and Linden Operating Partner, "We have the opportunity to redefine what's possible for regenerative medicine while making a meaningful difference in the lives of more patients around the world."
Polyganics' 75 employees will join the Collagen Matrix team, effective immediately, bringing Collagen Matrix's total employee count to more than 275 people across 5 sites globally including Polyganics' operations in The Netherlands.
Financials details of the transaction were not disclosed.